<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941848</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ROZE-102</org_study_id>
    <nct_id>NCT02941848</nct_id>
  </id_info>
  <brief_title>Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-Label, Two-way Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety After Administration of HCP1306 Tablet and Co-administration of HGP0816 Tablet, HGP1404 Tablet in the Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Pharmacokinetic Properties and Safety after&#xD;
      administration of HCP1306 tablet and Co-administration of HGP0816 tablet, HGP1404 tablet in&#xD;
      the healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-Label, Two-way Crossover, Single-Dose Study to Compare Pharmacokinetic&#xD;
      Properties and Safety after administration of HCP1306 tablet and Co-administration of HGP0816&#xD;
      tablet, HGP1404 tablet in the healthy adults&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT of Rosuvastatin</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT of Free Ezetimibe</measure>
    <time_frame>Pre-dose, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 36, 48, 72, 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C → A + B&#xD;
A : HGP0816 B : HGP1404 C : HCP1306</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A + B → C&#xD;
A : HGP0816 B : HGP1404 C : HCP1306</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0816</intervention_name>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1404</intervention_name>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1306</intervention_name>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Inclusion criteria]&#xD;
&#xD;
          1. Healthy adult of 19 to 50 of age at screening.&#xD;
&#xD;
          2. 18.5 ≤ Body mass index (BMI) &lt; 25.&#xD;
&#xD;
             ※ BMS (kg/m2)= body weight (kg)/[height (m)2]&#xD;
&#xD;
          3. Body weight ≥ 55 kg for men and ≥ 50 kg for women.&#xD;
&#xD;
          4. Individual considered by the responsible physician to be eligible as a subject based&#xD;
             on the results of hematology test, blood chemistry test, immunoserology test,&#xD;
             urinalysis, and electrocardiogram (ECG) as performed according to the characteristics&#xD;
             of the drug (including those with not clinically significant (NCS) abnormalities).&#xD;
&#xD;
          5. Women must have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test&#xD;
             at screening and a negative pre-dose urine β-hCG test at a time point defined in the&#xD;
             protocol and must be applicable to one of the followings.&#xD;
&#xD;
               -  Postmenopausal (no spontaneous menstruation for at least 2 years)&#xD;
&#xD;
               -  Surgical sterilization (sterilized by hysterectomy, bilateral ovariectomy or&#xD;
                  tubal ligation, or other methods)&#xD;
&#xD;
               -  A male partner is sterilized prior to screening (documented azoospermia following&#xD;
                  vasectomy) and this man is the subject's only partner.&#xD;
&#xD;
               -  The subject must agree to use adequate methods of contraception continuously and&#xD;
                  properly during the period of time from at least 14 days prior to the first dose&#xD;
                  to at least 28 days after the last dose of the investigational product.&#xD;
&#xD;
                    -  Adequate methods of contraception include abstinence and physical barrier&#xD;
                       methods (e.g., condom, diaphragm, or cervical cap) and contraceptive devices&#xD;
                       or pills containing hormones that may have drug-drug interactions with the&#xD;
                       investigational product are not to be used during the study period, in&#xD;
                       principle.&#xD;
&#xD;
          6. Sexually active male subject with a female partner of childbearing potential must&#xD;
             agree to avoid pregnancy (condom, etc.) during the study and to maintain adequate&#xD;
             methods of contraception and not donate sperms during the study and for 28 days after&#xD;
             the last dose of the investigational product (the methods of contraception are not&#xD;
             necessary if the male subject or his female partner is sterile).&#xD;
&#xD;
          7. After receiving and understanding sufficient explanations about the study, the&#xD;
             individual must voluntarily decide to participate in the study and provide written&#xD;
             informed consent to complying with study instructions.&#xD;
&#xD;
        [Exclusion criteria]&#xD;
&#xD;
          1. Evidence or history of clinically significant diseases in the hepatobiliary system,&#xD;
             kidney, nervous system, psychiatric system, respiratory system, endocrine system&#xD;
             (thyroid dysfunction, etc.), hemato-oncology, cardiovascular system, immune system, or&#xD;
             musculoskeletal system (myopathy, etc.).&#xD;
&#xD;
          2. History of gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis) or&#xD;
             surgery (except for simple typhlotomy or hernia repair) that may affect the absorption&#xD;
             of the investigational product.&#xD;
&#xD;
          3. Hypersensitivity reactions to any of the components of the investigational product or&#xD;
             its excipients or drugs of the same class.&#xD;
&#xD;
          4. Hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or&#xD;
             glucose-galactose malabsorption.&#xD;
&#xD;
          5. Vital signs measured in the sitting position after at least 5 minutes of rest as&#xD;
             follows: systolic blood pressure (SBP) &gt; 150 mmHg or &lt; 90 mmHg or diastolic blood&#xD;
             pressure (DBP) &gt; 100 mmHg or &lt; 50 mmHg.&#xD;
&#xD;
          6. Screening clinical laboratory test results as follows:&#xD;
&#xD;
               -  Blood total bilirubin level &gt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Blood aspartate aminotransferase (AST, also known as serum glutamic oxaloacetic&#xD;
                  transaminase [SGOT]) or alanine aminotransferase (ALT, also known as serum&#xD;
                  glutamate pyruvate transaminase [SGPT]) &gt; 1.25 x ULN&#xD;
&#xD;
               -  Blood urea nitrogen (BUN) &gt; 25.0 mg/dL or creatinine &gt; 1.4 mg/dL&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73m2 as calculated by&#xD;
                  the Modification of Diet in Renal Disease (MDRD) equation&#xD;
&#xD;
                  ※ eGFR (mL/min/1.73m2) = 175 x [serum creatinine (mg/dL)]-1.154 x [age&#xD;
                  (years)]-0.203 (X 0.742, if female)&#xD;
&#xD;
               -  Blood Creatinine Phosphokinase (CK) &gt; 2 x ULN&#xD;
&#xD;
          7. History of significant drug abuse within 1 year of screening or positive urine drug&#xD;
             test results.&#xD;
&#xD;
          8. Administration of drugs within 30 days of the investigational product administration&#xD;
             that are expected to or may affect the metabolism of the investigational product.&#xD;
&#xD;
          9. Administration of the following drugs within the relevant period, except for local&#xD;
             agents without significant systemic absorption and hormonal contraceptives.&#xD;
&#xD;
               -  Ethical (ETC) drugs within 14 days of the first investigational product&#xD;
                  administration&#xD;
&#xD;
               -  Over-the-counter (OTC) drugs including health foods and vitamin preparations&#xD;
                  within 7 days of the first investigational product administration&#xD;
&#xD;
               -  Drugs administered via depot injection or other implantations (except for&#xD;
                  contraceptives) within 30 days of the first investigational product&#xD;
                  administration&#xD;
&#xD;
         10. Significant alcohol dependency within 1 year of screening, continuous drinking within&#xD;
             6 months of screening (&gt; 210 g/week), or unable to refrain from drinking during the&#xD;
             study period starting from 2 days prior to the first investigational product&#xD;
             administration.&#xD;
&#xD;
         11. Continuous caffeine intake (e.g., coffee &gt; 5 cups/day, tea &gt; 1250 cc/day, cola &gt; 1250&#xD;
             cc/day) or unable to refrain from caffeine intake during the study period starting&#xD;
             from 2 days prior to the first investigational product administration.&#xD;
&#xD;
         12. Continuous smoking (&gt; 10 cigarettes/day) or unable to refrain from smoking during the&#xD;
             study period starting from 2 days prior to the first investigational product&#xD;
             administration.&#xD;
&#xD;
         13. Intake of grapefruits or foods containing grapefruits within 7 days prior to the first&#xD;
             investigational product administration.&#xD;
&#xD;
         14. Participation in another clinical trial (including a bioequivalence study) and&#xD;
             administration of another investigational product within 60 days prior to the&#xD;
             investigational product administration in this study (3 months for biologics; a&#xD;
             prolonged period of time may be applied with half life taken into account).&#xD;
&#xD;
         15. Whole blood donation within 60 days or apheresis donation within 30 days prior to the&#xD;
             investigational product administration.&#xD;
&#xD;
         16. Pregnant or lactating women.&#xD;
&#xD;
         17. Subject considered by the investigator to be inappropriate for study participation due&#xD;
             to other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choon Ok Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Health System, Severance Hospital</affiliation>
  </overall_official>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>October 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2016</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

